BioSpace · 新闻稿·· 12 天前AI 评分34
[临床][待核对]Palleon Pharmaceuticals宣布HLX79/E-602治疗自身免疫疾病数据将亮相2026 ASN Kidney Week口头报告
Palleon Pharmaceuticals Announces Late-Breaking Oral Presentation on HLX79/E-602 in Autoimmune Disease at the 2026 American Society of Nephrology (ASN) Kidney Week
AI 导读
Palleon Pharmaceuticals将于2026年美国肾脏病学会肾脏周（ASN Kidney Week）发布HLX79/E-602的迟发口头报告，报告标题为“HLX79（E-602）联合利妥昔单抗在膜性肾病患者中产生快速持久应答”。 公司：Palleon Pharmaceuticals 相关资产：HLX79/E-602 适应症：膜性肾病 阶段：Phase 2 融资性质：不适用 来源：BioSpace · 新闻稿（https://www.biospace.com/press-releases/palleon-pharmaceuticals-announces-late-breaking-oral-presentation-on-hlx79-e-602-in-autoimmune-disease-at-the-2026-american-society-of-nephrology-asn-kidney-week）
来源：BioSpace · 新闻稿 · biospace.com
正在验证登录状态…